Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Patients with structural heart disease are at risk for life-threatening ventricular tachycardias (VTs). Implantable cardioverter-defibrillators (ICDs) can terminate VT, but often at the cost of traumatic shocks, syncope, or even exacerbation of underlying heart disease. Catheter ablation for VT can reduce the need for ICD therapies and is an increasingly important adjunct to the treatment of these patients.
Klersy et al. have performed a meta-analysis of remote monitoring of patients with heart failure. Programs using structured telephone support (telephone-monitoring approach) were combined with those using transmission of physiological data (technology-assisted approach) in combination with telephone communication. Results from this study may inform policy makers regarding a potential solution to reducing hospital readmissions.
A continuous-flow left ventricular assist device (LVAD) improved survival free from disabling stroke compared with a pulsatile LVAD, when used as destination therapy over a 2-year period in patients with advanced heart failure. Both devices improved patient quality of life. Continuous-flow devices are smaller, lighter, and more simple than pulsatile LVADs and have the potential to fulfill all the requirements of a permanently implanted blood pump.
Stress cardiomyopathy, or Takotsubo syndrome, is a transient and reversible disorder that occurs suddenly after emotional or physical stress. It displays symptoms similar to acute myocardial infarction and is found predominantly in postmenopausal women. The underlying cause is still unknown. In this Review, the authors describe the published data relating to stress cardiomyopathy and discuss the possible mechanisms of this cardiac entity.
The introduction of drug-eluting stents (DES) has greatly reduced in-stent restenosis. Improvements to this technology are required, however, as safety and efficacy are still a problem. This Review describes current DES and the methods that are being used to optimize the performance of these stents. The author also suggests the direction of DES in the future, including tailored therapy to improve patient outcomes.
Cell therapy could improve cardiac function in patients with coronary heart disease. In this article, the authors provide an overview of the clinical trials in this field and highlight the limitations of cardiac cell therapy. They also discuss how these issues are being addressed and what the future may hold for this therapy.
Sudden cardiac arrest causes more than 60% of all deaths from cardiovascular disease. In this Review, Adabag and colleagues discuss trends in the incidence of sudden cardiac death (SCD), and the risk factors and triggers of this devastating event. The authors also highlight the lack of a concise definition for SCD and suggest that prospective community surveillance programs, using multiple sources to identify cases, would enable more accurate determination of SCD burden. They also review the growing evidence for the role of public-access defibrillators in improving survival after sudden cardiac arrest.
Imaging techniques that assess myocardial perfusion and coronary anatomy obtain complementary information. Simultaneous dual-modality or sequential multimodal imaging techniques facilitate integration of this information, and thus have the potential to improve diagnostic and prognostic evaluations, as well as care of patients. This Review discusses the clinical utility and future directions of hybrid imaging.
